Article Text

Download PDFPDF
Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway
  1. Petra Bohanec Grabar1,
  2. Sabina Rojko1,
  3. Dušan Logar2,
  4. Vita Dolžan1
  1. 1Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
  2. 2Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
  1. Correspondence to Vita Dolžan, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia; vita.dolzan{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Methotrexate (MTX) is a disease-modifying antirheumatic drug (DMARD) used for the treatment of rheumatoid arthritis (RA). Genetic polymorphisms in AMP deaminase (AMPD1), 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ATIC), inosine triphosphate pyrophosphorylase (ITPA) and methylenetetrahydrofolate dehydrogenase (MTHFD1) were shown to be associated with disease activity, MTX treatment response and MTX-induced toxicity in patients with RA.1,,6 The aim of our study was to test these associations in Slovenian patients with RA treated with MTX.

Our study included 211 patients with RA who were previously characterised.7 Among them, 98 patients were receiving MTX monotherapy, 57 co-treated with one or more DMARD and 56 discontinued MTX before enrolment owing to MTX inefficacy and/or toxicity. The 28-joint count Disease Activity Score (DAS28) …

View Full Text


  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the Slovenian Ethics Committee for Research in Medicine.

  • Provenance and peer review Not commissioned; externally peer reviewed.